Skip to main content
Clinical Trials/EUCTR2015-005155-27-HR
EUCTR2015-005155-27-HR
Active, not recruiting
Phase 1

Comparison of the efficacy and safety of the fixed-dose combination of xylometazoline and dexpanthenol in SeptaNazal® and xylometazoline in nasal congestion in patients after surgery in the nose and paranasal cavity and in patients with acute rhinitis – SeptaNazal DOUBLE clinical study.

KRKA-FARMA d.o.o.0 sites223 target enrollmentDecember 15, 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
KRKA-FARMA d.o.o.
Enrollment
223
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 15, 2016
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with acute rhinitis (Group 1\):
  • Aged 18\-60 years
  • Diagnosed with acute rhinitis
  • Can carry out intranasal administration of the investigational medicinal
  • Signed Informed consent form
  • Patients after nasal surgery or nasal cavities surgery (Group 2\):
  • Aged 18\-60 years
  • Recent nasal surgery or nasal cavities surgery (patients with chronic
  • rinosinusitis with nasal polyps (CRSwNP) and patients with chronic
  • rinosinusitis without nasal polyps (CRSsNP)

Exclusion Criteria

  • Hypersensitivity to the active substances or to any of the excipients
  • Dry nasal inflammation (rhinitis sicca)
  • History of transsfenoidal hypophysectomy or other surgical procedures in which the dura mater was exposed
  • Patients who are treated with drugs for local or systemic treatment of influenza, and sympathomimetic agents, which contain a medicament for the treatment for cough and/or cold
  • Pregnancy or breast\-feeding
  • Patients with asthma who require treatment with corticosteroids
  • Rhinitis medicamentosa
  • Chronic rhinitis
  • Patients treated with monoamine oxidase inhibitors (MAOIs) or other drugs that may raise blood pressure
  • Patients with increased intraocular pressure, in particular with angle\-closure glaucoma

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Comparison of the efficacy and safety of the fixed-dose combination of xylometazoline and dexpanthenol in SeptaNazal® and xylometazoline in nasal congestion in patients after surgery in the nose and paranasal cavity and in patients with acute rhinitis – SeptaNazal DOUBLE clinical study.asal congestion in patients after nasal surgery or nasal cavities surgery and in patients with acute rhinitisMedDRA version: 19.0Level: HLTClassification code 10028736Term: Nasal congestion and inflammationsSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]
EUCTR2015-005155-27-SIKrka, d.d., Novo mesto194
Not yet recruiting
Phase 4
To evaluate efficacy and safety of three drug combinations in patients with community acquired pneumonia and acute exacerbation of chronic bronchitisHealth Condition 1: null- community acquired pneumonia and acute exacerbation of chronic bronchitis
CTRI/2012/01/002347Dr Sharif Tadvi80
Not yet recruiting
Not Applicable
A comparative study of effectiveness of Alpha2 agonist (Dexmedetomidine) versus opioid (fentanyl) for awake intubation using flexible bronchoscopeHealth Condition 1: O- Medical and Surgical
CTRI/2022/03/041196Vinayaka missions kirupanda variyar medical college and hospital
Not yet recruiting
Phase 2
A clinical trial to study the effects of two drugs, metformin lotion and zinc oxide cream in patients with melasma, a type of facial pigmentatioHealth Condition 1: L811- Chloasma
CTRI/2023/09/057901ITHYAMS
Completed
Phase 3
A clinical trial to study the effects of artesunate - lumefantrine combination and artemether - lumefatrine combination in the treatment of uncomplicated Plasmodium falciparum malaria.Health Condition 1: null- Uncomplicated Plasmodium falciparum malaria
CTRI/2009/091/000434Ipca Laboratories Limited176